title: [Comparative study of high doses vs conventional doses of cytosine arabinoside combined with cisplatin and dexamethasone in patients with refractory lymphoma].
abstract: Forty-three patients with advanced malignant lymphoma resistant to previous chemotherapy were randomized in two groups: one received a high dose versus a low-dose cytosine arabinoside, in combination with dexamethasone and cisplatinum. Ten of 24 patients (41%) in the low-dose regimen achieved response: six complete remission (CR) and four partial remission (PR), compared with 5 of 19 (30%) (three CR and two PR). Survival was better in the low dose regimen: 39 versus 23 weeks. Toxicity was most frequent and severe in the high dose schedule. These results suggests that the use of cytosine arabinoside and cisplatinum is useful in the treatment of refractory lymphoma, and that the low-dose would be a better alternative than a high dose.
authors.affiliation: Departamento de Hematologia, Hospital de Oncologia, Centro Médico Nacional, IMSS, México, D.F.
authors.forename: A
authors.initials: A
authors.lastname: Avilés
authors.forename: E L
authors.initials: EL
authors.lastname: García
authors.forename: R
authors.initials: R
authors.lastname: Guzmán
authors.forename: A
authors.initials: A
authors.lastname: Talavera
authors.forename: J J
authors.initials: JJ
authors.lastname: Poot
authors.forename: J C
authors.initials: JC
authors.lastname: Díaz-Maqueo
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction
chemical_list: D003561:Cytarabine; D003907:Dexamethasone; D002945:Cisplatin
vernacular_title: Estudio comparativo de dosis altas vs dosis convencionales de arabinósido de citosina en combinación con cisplatino y dexametasona en pacientes con linfoma refractario.